Search

Displaying results 8811 - 8820 of 10000 in total
  1. Drug

    Saracatinib

    go.drugbank.com/drugs/DB11805
    Investigational

    Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

  2. Drug

    LTX-109

    go.drugbank.com/drugs/DB12711
    Investigational

    LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.

  3. Drug

    Tantalum

    go.drugbank.com/drugs/DB12859
    Investigational

    Tantalum has been investigated for the treatment and prevention of Osteoarthritis, Knee Osteoarthritis, Intraoperative Bleeding, and Adolescent Idiopathic Scoliosis.

  4. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    It was developed by Sixal Inc.

  5. Drug

    Iomethin I-125

    go.drugbank.com/drugs/DB20779
    Experimental

    Iomethin I-125 has a monoisotopic molecular weight of 353.05 Da.

  6. Drug

    Bacillus calmette-guerin substrain connaught live antigen

    go.drugbank.com/drugs/DB10804
    ApprovedInvestigationalWithdrawn

    Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary

  7. Drug

    8-azaguanine

    go.drugbank.com/drugs/DB01667
    Experimental

    It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

  8. Drug

    Ruboxistaurin

    go.drugbank.com/drugs/DB11829
    Investigational

    Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.

  9. Drug

    2,4-thiazolidinedione

    go.drugbank.com/drugs/DB11898
    Investigational

    Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2.

  10. Drug

    Golvatinib

    go.drugbank.com/drugs/DB11977
    Investigational

    Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.